文献速递肿瘤 PET/CT放射性药物与辐射防护

复发或转移性头颈癌患者度伐利尤单抗治疗前行89Zr-DFO-度伐利尤单抗PET/CT

89Zr-DFO-Durvalumab PET/CT Before Durvalumab Treatment in Patients with Recurrent or Metastatic Head and Neck Cancer.
PubMed 文献 · J Nucl Med · 2022-05-05

PINCH研究为前瞻性多中心I-II期试验,在33例复发或转移性头颈鳞癌患者度伐利尤单抗单药治疗前行89Zr-DFO-度伐利尤单抗PET/CT,评估安全性和可行性并预测疾病控制率。结果显示该显像安全可行,但肿瘤摄取不能预测度伐利尤单抗治疗反应。

要点

  • 89Zr-DFO-度伐利尤单抗PET/CT在复发或转移性头颈鳞癌中安全可行。
  • 患者水平SUVpeak或肿瘤/血池比不能预测治疗反应(HR 1.5和1.3)。
  • 病灶水平摄取与PD-L1联合阳性评分无关,与18F-FDG SUVpeak相关(ρ=0.391)。

核心结论

  • PINCH是首个在复发或转移性头颈鳞癌患者中进行的PD-L1 PET/CT研究,多中心试验显示89Zr-DFO-度伐利尤单抗PET/CT的可行性和安全性。
  • 89Zr-DFO-度伐利尤单抗摄取与度伐利尤单抗治疗反应无关。

研究设计与样本

  • 前瞻性多中心I-II期研究(NCT03829007),纳入33例不可治愈的复发或转移性头颈鳞癌患者。
  • 患者先行基线18F-FDG PET和CT或MRI,随后在给予37 MBq 89Zr-DFO-度伐利尤单抗后5天行PD-L1 PET显像。
  • 前14例患者进行剂量探索以优化显像条件。
  • 所有患者(n=33)在PD-L1 PET显像后1周内开始度伐利尤单抗治疗(1,500 mg/4周,静脉给药),持续至疾病进展或不可接受毒性(最长24个月)。
  • 每8周按RECIST 1.1进行CT评估;PD-L1表达采用(存档)肿瘤组织的联合阳性评分确定。

主要发现

  • 共纳入33例患者,其中局部区域复发12例、转移性21例。
  • 89Zr-DFO-度伐利尤单抗注射安全;10 mg度伐利尤单抗剂量获得最高肿瘤/血池比。
  • 中位随访12.6个月后,总缓解率为26%;16周疾病控制率为48%,平均持续时间7.8个月(范围1.7-21.1)。
  • 患者水平89Zr-DFO-度伐利尤单抗SUVpeak或肿瘤/血池比不能预测治疗反应(风险比分别为1.5 [95%CI 0.5-3.9;P=0.45]和1.3 [95%CI 0.5-3.3;P=0.60])。
  • 病灶水平89Zr-DFO-度伐利尤单抗SUVpeak与治疗反应无实质性相关性(Spearman ρ=0.45;P=0.051);病灶摄取与PD-L1联合阳性评分无关,但与18F-FDG SUVpeak相关(Spearman ρ=0.391;P=0.005)。

关键数值与推荐

  • 89Zr-DFO-度伐利尤单抗给药活度为37 MBq,显像时间为给药后5天。
  • 度伐利尤单抗治疗方案为1,500 mg/4周静脉给药,最长持续24个月。
  • 疗效评估采用RECIST 1.1每8周进行。
  • PD-L1表达采用联合阳性评分(CPS)确定。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In this PD-L1 ImagiNg to prediCt durvalumab treatment response in SCCHN (PINCH) study, we performed 89Zr-DFO-durvalumab (anti-PD-L1 [programmed death ligand 1]) PET/CT in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) before monotherapy durvalumab treatment. The primary aims were to assess safety and feasibility of 89Zr-DFO-durvalumab PET imaging and predict disease control rate during durvalumab treatment. Secondary aims were to correlate 89Zr-DFO-durvalumab uptake to tumor PD-L1 expression, 18F-FDG uptake, and treatment response of individual lesions. Methods: In this prospective multicenter phase I-II study (NCT03829007), patients with incurable R/M SCCHN underwent baseline 18F-FDG PET and CT or MRI. Subsequently, PD-L1 PET imaging was performed 5 d after administration of 37 MBq of 89Zr-DFO-durvalumab. To optimize imaging conditions, dose finding was performed in the first 14 patients. For all patients (n = 33), durvalumab treatment (1,500 mg/4 wk, intravenously) was started within 1 wk after PD-L1 PET imaging and continued until disease progression or unacceptable toxicity (maximum, 24 mo). CT evaluation was assessed according to RECIST 1.1 every 8 wk. PD-L1 expression was determined by combined positive score on (archival) tumor tissue. 89Zr-DFO-durvalumab uptake was measured in 18F-FDG-positive lesions, primary and secondary lymphoid organs, and blood pool. Results: In total, 33 patients with locoregional recurrent (n = 12) or metastatic SCCHN (n = 21) were enrolled. 89Zr-DFO-durvalumab injection was safe. A dose of 10 mg of durvalumab resulted in highest tumor-to-blood ratios. After a median follow-up of 12.6 mo, overall response rate was 26%. The disease control rate at 16 wk was 48%, with a mean duration of 7.8 mo (range, 1.7-21.1). On a patient level, 89Zr-DFO-durvalumab SUVpeak or tumor-to-blood ratio could not predict treatment response (hazard ratio, 1.5 [95% CI, 0.5-3.9; P = 0.45] and 1.3 [95% CI, 0.5-3.3; P = 0.60], respectively). Also, on a lesion level, 89Zr-DFO-durvalumab SUVpeak showed no substantial correlation to treatment response (Spearman ρ, 0.45; P = 0.051). Lesional 89Zr-DFO-durvalumab uptake did not correlate to PD-L1 combined positive score but did correlate to 18F-FDG SUVpeak (Spearman ρ, 0.391; P = 0.005). Conclusion: PINCH is the first, to our knowledge, PD-L1 PET/CT study in patients with R/M SCCHN and has shown the feasibility and safety of 89Zr-DFO-durvalumab PET/CT in a multicenter trial. 89Zr-DFO-durvalumab uptake did not correlate to durvalumab treatment response.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Verhoeff SR, van de Donk PP, Aarntzen EHJG, et al. 89Zr-DFO-Durvalumab PET/CT Before Durvalumab Treatment in Patients with Recurrent or Metastatic Head and Neck Cancer. J Nucl Med. 2022. PMID: 35512998. doi:10.2967/jnumed.121.263470

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。